Search Follow us

BB Biotech (BION)

Business description

BION is a Switzerland-domiciled investment company, targeting attractive long-term returns from predominantly mid-/large-cap biotech companies with established product portfolios (sales and earnings) and promising pipeline candidates. It is benchmarked against the NASDAQ Biotech Index, but is managed bottom-up with a concentrated 20-35 stock portfolio.

Stock data

Market cap.CHF3839.2m
Last closeCHF69.30
High / Low (52 weeks)CHF74.1 / CHF56.1
Stock market listingSW, IM
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamInvestment Companies
SectorInvestment trusts

Other companies in sector Show

Aberdeen Asian Income Fund Aberdeen Latin American Income Fund
Aberdeen New Dawn Investment Trust Aberdeen New Thai Investment Trust
Aberdeen Private Equity Fund Aberdeen Standard Equity Income Trust
Aberdeen UK Tracker Trust AcenciA Debt Strategies
Acorn Income Fund Adamas Finance Asia
Alliance Trust Altamir SCA
Amphion Innovations Atlantis Japan Growth Fund
Aurelius Bailador Tech Investments
Baker Steel Resources Trust Bankers Investment Trust (The)
BioPharma Credit BlackRock Emerging Europe
BlackRock Greater Europe Investment Trust BlackRock Hedge Selector
BlackRock Latin American Inv. Trust BMO Managed Portfolio Trust Growth Portfolio
BMO Managed Portfolio Trust Income Portfolio British Portfolio Trust
Brunner Investment Trust (The) Canadian General Investments
Carador Income Fund CFP Sanford DeLand Free Spirit Fund.
Charles Stanley City Natural Resources
Conversus Capital CQS Rig Finance Fund
CVC Credit Partners European Opps Detour Gold
Deutsche Beteiligungs Dexion Commodities
Diverse Income Trust (The) DouglasBay Capital
Dunedin Enterprise Investment Trust DW Catalyst Fund
Edinburgh Worldwide Investment Trust (The) EJF Investments
European Assets Trust F&C Investment Trust
Fidelity Asian Values Fidelity China Special Situations
Fidelity European Values Fidelity Japan Trust
Fidelity Special Values Finsbury Growth & Income Trust
Gartmore Growth Opportunities Gartmore Irish Growth Fund
Geiger Counter Limited Genesis Emerging Markets Fund
GLI Alternative Finance Global Resources Investment Trust
Golden Prospect Precious Metals Gulf Investment Fund
Hansa Trust HarbourVest Global Private Equity
HarbourVest Senior Loans Europe HBM Healthcare Investments
Heliad Equity Partners Henderson Alternative Strategies Trust
Henderson Far East Income Henderson Global Trust
Henderson Global Trust Henderson International Income Trust
Heptagon HSBC Infrastructure Company
Infrastructure India International Biotechnology Trust
Invesco Asia Trust Invesco Income Growth Trust
Is Private Equity JP Morgan Private Equity Limited
JPMorgan Brazil Investment Trust JPMorgan European Smaller Companies Trust
JPMorgan Global Convertibles Income Fund JPMorgan Global Growth & Income
JPMorgan Indian Investment Trust Jupiter Green Investment Trust
Jupiter UK Growth Investment Trust Jupiter US Smaller Companies
JZ Capital Partners Limited Lazard World Trust Fund
Leaf Clean Energy Company LMS Capital
Lowland Investment Company LPeC
Marble Point Loan Financing Martin Currie Asia Unconstrained Trust
Martin Currie Global Portfolio Trust Middlefield Canadian Income
Miton Global Opportunities Miton Income Opportunities Trust
Murray Income Trust Murray International Trust
New City Energy Ocean Wilsons Holdings
Odyssean Investment Trust Pacific Assets Trust
Phaunos Timber Fund Polar Capital Global Financials Trust
Polar Capital Global Healthcare Trust Princess Private Equity Holding
PXP Vietnam Fund Rathbone Brothers
RENN Universal Growth Investment Trust Schroder AsiaPacific Fund
Schroder Global Real Estate Securities ScotGems
Scottish Oriental Smaller Companies Sealand Capital Galaxy
Securities Trust of Scotland Seneca Global Income & Growth Trust
Sigma Capital Group Standard Life Investments Property Income Trust
Standard Life Private Equity Trust Standard Life UK Smaller Companies
Strategic Equity Capital Taiwan Fund (The)
Templeton Emerging Markets Investment Trust Tetragon Financial Group
The Biotech Growth Trust The European Investment Trust
The Global Sustainability Trust The Law Debenture Corporation
The Merchants Trust The North American Income Trust
The Scottish Investment Trust Tiso Blackstar Group
Toscafund Asset Management TR European Growth Trust
UK Commercial Property REIT Utilico Emerging Markets Trust
Vietnam Enterprise Investments Vietnam Holding Asset Management
Vietnam Infrastructure Fund VinaCapital Vietnam Opportunity Fund
VinaLand Vision Opportunity China Fund
Volta Finance WAM Active
WAM Capital WAM Research
Witan Investment Trust Witan Pacific Investment Trust
Worldwide Healthcare Trust YFM Equity Partners

Company news

Bb Biotech Ag Buys Tesaro Inc, argenx SE, Akcea Therapeutics Inc, Sells Juno ...

Tue, 08 May 2018 23:37:30 GMT

BRIEF-BB Biotech Q1 Profit Of CHF 28 Mln

Fri, 20 Apr 2018 05:03:45 GMT

Bb Biotech Ag Now Owns 2362964 Shares In Esperion Therapeutics, Inc. (ESPR)

Thu, 03 May 2018 10:07:30 GMT

Neurocrine Biosciences (NBIX) Shares Sold by BB Biotech AG

Wed, 16 May 2018 11:37:30 GMT

What Does the 4 F-Score For BB Biotech AG (SWX:BION) Reveal?

Mon, 14 May 2018 11:23:52 GMT

Investment summary

BB Biotech (BION) is a Switzerland-based closed-end fund focusing on the high-growth opportunities available in the global biotechnology space. Founded in 1993 by industry specialist Bellevue Asset Management, BION holds a concentrated (c 30–35 stocks) portfolio of biotech names, which are diversified across a range of clinical focuses. The fund’s strong record of NAV outperformance versus the headline NASDAQ Biotechnology index has suffered a setback in the past 12 months. However, the managers remain optimistic on medium-term clinical catalysts and have recently refreshed the portfolio with a number of new holdings. BION has a policy of paying c 5% of its share price annually as a dividend, which, along with a shift in the shareholder base to include more long-term investors and fewer discount players, has supported a strong re-rating in the shares. The fund has traded at an average 7.1% premium to NAV in the past 12 months.

Last updated on 25/10/2018

Latest video

Bitesize Briefings - BB Biotech

Key management

Prof. Dr. Thomas Szucs, Chairman
Daniel Koller, Head of Management Team
Claude Mikkelsen, Director of IR
Dr. Silvia Schanz , Investor Relations

Company address

Seestrasse 16
Postfach
8700 Kusnacht / Zurich
Germany
+41 44 267 67 00
View website